The Mycobacterium genus has important pathogenic species, such as M. leprae and M. tuberculosis, with high incidence in the human population. The number of bacterial strains resistant to antibiotics is steadily increasing, and in particular no new antibiotics have been developed for Mycobacterium. Mycobacteriophages have been shown to be viable alternatives, mainly to counteract antibiotic-resistant bacteria. A new mycobacteriophage (Myms-1) was isolated from sewage in Manaus, Amazonas state, Brazil, with lytic activity against M. smegmatis. Morphological analysis of the Mysm-1 phage shows that it probably belongs to the genus Fromanvirus (family Siphoviridae). It has an icosahedral head with approximate diameter of 50 nm and a long non-contractile tail with approximate length of 200 nm. M. smegmatis is a fast-growing mycobacterium found in the environment that is normally non-pathogenic, so it is a promising bacterium for initial tests of this genus.
A. Coros, E. Deconno, K. M. Derbyshire, “IS6110, a Mycobacterium tuberculosis complex-specific insertion sequence, is also present in the genome of Mycobacterium smegmatis, suggestive of lateral gene transfer among Mycobacterial species,” Journal of Bacteriology, vol. 190(9), pp. 3408-3410, May 2008.
World Health Organization. 2018. “Global tuberculosis report 2020”. World Health Organization, Geneva, Switzerland. https://www.who.int/tb/publications/global_report/en/.
K. Hruska, M. Kaevska, “Mycobacteria in water, soil, plants and air: a review,” Veterinarni Medicina, vol. 57(12), pp. 623–679, 2012.
4 G. F. Hatfull, “Mycobacteriophages,” Microbiology spectrum, vol. 6(5) Oct. 2018.
X. Z. Li, L. Zhang, H. Nikaido, “Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis,” Antimicrobial Agents Chemotherapy, vol. 48(7), pp. 2415-2423. Jul. 2004.
6 A. K. Singh J. M. Reyrat, “Laboratory Maintenance of Mycobacterium smegmatis,” Current Protocols in Microbiology, vol. 14, pp. 1–10, Aug. 2009.
E. W. Schultz, “The bacteriophage as a therapeutic agent,” California and Western Medicine, vol. 31(1), pp. 5-10, Jul. 1929.
S. Reardon, “Phage therapy gets revitalized: The rise of antibiotic resistance rekindles interest in a century-old virus treatment,” Nature, vol. 5;510(7503), pp. 15-16. Jun. 2014.
A. Sulakvelidze, Z. Alavidze, J. G. Morris, “Bacteriophage Therapy,” Antimicrobial Agents and Chemotherapy, vol. 45(3), pp. 649–659, Mar. 2001.
C. Loc-Carrillo, S. T. Abedon, “Pros and cons of phage therapy Bacteriophage Landes,” Bioscience, vol. 1(2), pp. 111-114, Mar 2011.
E. Li, X. Wei, Y. Ma, Z. Yin, H. Li, W. Lin, X. Wang, C. Li, Z. Shen, R. Zhao, H. Yang, A. Jiang, W. Yang, J. Yuan, X. Zhao, “Isolation and characterization of a bacteriophage phiEap-2 infecting multidrug resistant Enterobacter aerogenes”, Scientific Reports, vol. 20;6:28338 Jun. 2016.
A. C. C. de Melo, A. da Mata Gomes, F. L. Melo, D. M. P. Ardisson-Araújo, A. P. C. de Vargas, V. L. Ely, E. W. Kitajima, B. M. Ribeiro, J. L. C. Wolff “Characterization of a bacteriophage with broad host range against strains of Pseudomonas aeruginosa isolated from domestic animals,” BMC Microbiology. vol. 17;19(1):134, Jun. 2019.
H. W. Ackermann, “5500 Phages examined in the electron microscope,” Archhives of Virology, vol. 152(2), pp. 227-243, Feb. 2007.
G. F. Hatfull, “Mycobacteriophages: windows into tuberculosis”. PLoS Pathogens, vol. 20;10(3):e1003953, Mar. 2014.
B. Stewart, M. Adams, M. Fuentes, L. Hanson, E. Sandoval, M. Tovar, C. Trautman, B. Willis, K. Emmert, J. Edwards, J. Meik, J. Pierce, D. Edwards, “Complete Genome Sequence of Cluster A1 Mycobacterium smegmatis Bacteriophage Arlo,” Microbiology Resource Announcements, vol. 25;7(16):e01242-18. Oct. 2018.
M. K. Donnelly‐Wu, W. R. Jacobs Jr, G. F. Hatfull, “Superinfection immunity of mycobacteriophage L5: applications for genetic transformation of mycobacteria,” Molecular Microbiology, vol. 7(3), pp. 407-417, Feb. 1993.
D. Veesler, C. Cambillau, “A common evolutionary origin for tailed-bacteriophage functional modules and bacterial machineries,” Microbiology and Molecular Biology Review, vol. 75(3), pp. 23-33, Sep. 2011.
N. B. Carrigy, S. E. Larsen, V. Reese, T. Pecor, M. Harrison, P. J. Kuehl, G. F. Hatfull, D. Sauvageau, S. L. Baldwin, W. H Finlay, R. N. Coler, R. Vehring, “Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29,” Antimicrob Agents Chemother, vol. 16;63(12):e00871-19, Sep. 2019.
C. C. Tseng, D. C. Chang, K. C. Chang, “Development of a Biocontrol Method Applying Bacteriophage-Containing Aerosol against Mycobacterium tuberculosis Using the Bacteriophage BTCU-1 and M. smegmatis as Models,” Microorganisms, vol. 3;7(8):237, Aug. 2019.
M. J. Lai, C. C. Liu, S. J. Jiang, P. C. Soo, M. H. Tu, J. J. Lee, Y. H. Chen, K. C. Chang, “Antimycobacterial Activities of Endolysins Derived From a Mycobacteriophage, BTCU-1,” Molecules, vol. 22;20(10), pp. 19277-19290, Oct. 2015.
M. Jamal, T. Hussain, C. Rajanna, S Andleeb, “Isolation and Characterization of a Myoviridae MJ1 Bacteriophage Against Multi-Drug Resistant Escherichia coli 3”, Jundishapur Journal of Microbiology, vol. 21;8(11):e25917, nov. 2015.
Y. Chang, H. Shin, J. Lee, C. J. Park, S. Y. Paik, S. Ryu, “Isolation and Genome Characterization of the Virulent Staphylococcus aureus Bacteriophage SA97” Viruses, vol. 7(10 ), pp. 5225–5242, Oct 2015.
C. R. Hsu, T. L. Lin, Y. J. Pan, P. F. Hsieh, J. T. Wang, “Isolation of a bacteriophage specific for a new capsular type of Klebsiella pneumoniae and characterization of its polysaccharide depolymerase”, PLoS ONE, vol. 2;8(8):e70092 Aug, 2013.
P. Domingo‐Calap, P. Georgel, S. Bahram, “Back to the future: bacteriophages as promising therapeutic tools” HLA, vol. 87 pp.133–140, 2016.
D. Romero-Calle, R. G. Benevides, A. Góes-Neto, C. Billington, “Bacteriophages as Alternatives to Antibiotics in Clinical Care”, Antibiotics (Basel), vol. 4;8(3):138. 2019.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.